Global Embolotherapy Market Research Report: Industry Analysis and Forecast to 2024 - North America is Predicted to Account for 40% of the Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Embolotherapy Market Research Report: By Product, Procedure, Indication, End - User, Geographical Outlook - Global Industry Analysis and Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

In 2018, the global embolotherapy market generated a revenue of $3.0 billion and is expected to attain $4.8 billion by 2024, advancing at a 8% CAGR during the forecast period (2019-2024).

In terms of product, embolic agents are projected to account for the larger share of the market and register the faster growth during the forecast period. The reason for this is the rising adoption of these agents for several interventional radiology procedures.

On the basis of procedure, transcatheter arterial embolization (TAE) is predicted to advance at the fastest pace in the embolotherapy market during the forecast period.

A key factor contributing to the growth of the embolotherapy market is the rising patient pool. The increasing adoption of embolic procedures for managing several diseases is occurring due to the growing patient pool and surging healthcare spending. Moreover, the patients diagnosed at advanced and intermediate stages do not respond to curative therapies, including liver transplantation, ablation, and surgical reaction. Hence, the surging pool of patients, who are at an advanced stage of different life-threatening diseases, need embolotherapy intervention, which is resulting in the growth of the market.

Geographically, North America is predicted to account for approximately 40.0% of the embolotherapy market in 2024 due to the increasing cases of chronic diseases and surging geriatric population.

In the European region, Germany is projected to lead the embolotherapy market throughout the forecast period because of the increasing healthcare expenditure, rising awareness regarding preventive care, growing adoption of advanced healthcare techniques, and presence of established players.

China is expected to hold the largest market share in the APAC region during the forecast period due to the growing demand for minimally invasive procedures and positive reimbursement scenario.

Key Topics Covered:

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Increase in the number of product approvals and launches

4.2.1.2 Increasing number of acquisitions

4.2.2 Drivers

4.2.2.1 Growing patient pool for embolotherapy

4.2.2.2 Increasing prevalence of chronic and lifestyle-associated diseases

4.2.2.3 Growing medical tourism

4.2.2.4 Rising healthcare expenditure and improving healthcare infrastructure

4.2.2.5 Growing preference for MISs

4.2.2.6 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Risks and challenges associated with embolization

4.2.3.2 Product recalls

4.2.3.3 Dearth of skilled radiologists

4.2.3.4 Impact analysis of restraints on market forecast

4.2.4 Opportunities

4.2.4.1 Growing applications of embolic agents

4.2.4.2 Untapped market in developing economies

4.3 Porter's Five Forces Analysis

4.4 Regulatory Framework Analysis

4.4.1 U.S.

4.4.2 Europe

4.4.3 APAC

4.4.4 LATAM

4.4.5 MEA

Chapter 5. Embolotherapy Procedures in 7MM

5.1 7MM

5.2 U.S.

5.3 U.K.

5.4 Germany

5.5 France

5.6 Italy

5.7 Spain

5.8 Japan

Chapter 6. Global Market Size and Forecast

6.1 Global Market Size and Forecast

6.2 By Product

6.2.1 Embolic Agents Market, by Type

6.2.2 Embolotherapy Support Devices Market, by Type

6.3 By Procedure

6.4 By Indication

6.4.1 Embolotherapy Market for Cancer, by Type

6.4.2 Embolotherapy Market for Neurological Diseases, by Type

6.5 By End User

6.6 By Region

Chapter 7. North America Market Size and Forecast

7.1 By Product

7.1.1 Embolic Agents Market, by Type

7.1.2 Embolotherapy Support Devices Market, by Type

7.2 By Procedure

7.3 By Indication

7.3.1 Embolotherapy Market for Cancer, by Type

7.3.2 Embolotherapy Market for Neurological Diseases, by Type

7.4 By End User

7.5 By Country

7.5.1 U.S. Market Size and Forecast

7.5.1.1 By product

7.5.1.1.1 Embolic agents market, by type

7.5.1.1.2 Embolotherapy support devices market, by type

7.5.1.2 By procedure

7.5.1.3 By indication

7.5.1.3.1 Embolotherapy market for cancer, by type

7.5.1.3.2 Embolotherapy market for neurological diseases, by type

7.5.1.4 By end user

7.5.2 Canada Market Size and Forecast

7.5.2.1 By product

7.5.2.1.1 Embolic agents market, by type

7.5.2.1.2 Embolotherapy support devices market, by type

7.5.2.2 By procedure

7.5.2.3 By indication

7.5.2.3.1 Embolotherapy market for cancer, by type

7.5.2.3.2 Embolotherapy market for neurological diseases, by type

7.5.2.4 By end user

Chapter 8. Europe Market Size and Forecast

Chapter 9. APAC Market Size and Forecast

Chapter 10. LATAM Market Size and Forecast

Chapter 11. MEA Market Size and Forecast

Chapter 12. Competitive Landscape

12.1 List of Other Players

12.2 Strategic Developments of Key Players

12.2.1 Product Launches & Approvals

12.2.2 Collaborations

12.2.3 Acquisitions

12.2.4 Expansions

Chapter 13. Company Profiles

13.1 Stryker Corporation

13.2 Sirtex Medical Limited

13.3 Merit Medical Systems Inc.

13.4 Meril Life Sciences Pvt. Ltd.

13.5 Acandis GmbH

13.6 Terumo Corporation

13.7 Medtronic plc

13.8 Kaneka Corporation

13.9 Johnson & Johnson

13.10 Boston Scientific Corporation

13.11 Abbott Laboratories

13.12 Guerbet

13.13 BALT EXTRUSION SAS

For more information about this report visit https://www.researchandmarkets.com/r/29i0g3